Tax Reforms Key to Modernizing Pakistan’s Pharmaceutical Sector

Rebalancing Taxes to Strengthen Pakistan’s Pharma Industry

Pakistan’s pharmaceutical sector is recognized as a strategic national asset. It safeguards public health, generates export earnings, and provides skilled employment. Yet, the industry is struggling under one of the country’s heaviest cumulative tax burdens, which inflates medicine costs and undermines competitiveness.

Currently, the sector faces a 47% effective tax load, including corporate tax, super tax, Workers’ Profit Participation Fund (WPPF), Workers’ Welfare Fund (WWF), Central Research Fund (CRF), and sales taxes. Retroactive levies like the 2022 super tax have added uncertainty, making planning and cash flow management increasingly difficult for firms producing essential medicines.

The Problem with Cascading Taxes

Sales tax policies are particularly damaging. A 1% “full and final” sales tax across the supply chain offers no input adjustment, effectively taxing tax. Distributors pass these costs back to manufacturers, creating hidden markups that ultimately burden patients. Additional levies on finished goods, imported packaging, and minimum value additions compound the problem.

Central Research Fund Concerns

The CRF, set at 1% of profit before tax, was intended to support research and regulatory capacity. However, it has failed to deliver measurable outcomes. Estimates suggest collections of PKR 140–150 billion over time, funds that could have been reinvested into manufacturing capacity, compliance, and supply resilience. Experts now call for its abolition and transparent reallocation of existing funds.

Super Tax Reform

The super tax has been applied unpredictably, creating cash flow pressures. Analysts recommend making it time-bound, non-retroactive, and clearly communicated. Relief should be targeted toward essential medicine lines and export income to protect supply and competitiveness.

Proposed Solutions

• Exempt or zero-rate sales tax for pharmaceuticals, with timely refunds for exports.
• Remove taxes on packaging materials to avoid double taxation.
• Abolish the CRF and redirect funds transparently.
• Redesign super tax rules to ensure predictability and fairness.
• Introduce export-linked incentives and accelerated depreciation for plant and machinery to stimulate modernization.
• Reassess statutory levies like WPPF and WWF with transparent reporting.

The Bigger Picture

These reforms are not about unchecked relief but about calibrated rebalancing. Lowering avoidable costs will protect medicine availability and quality, while modernizing the sector will expand exports and strengthen Pakistan’s healthcare system.

By addressing cascading taxes, abolishing outdated levies, and incentivizing modernization, Pakistan can transform its pharmaceutical sector into a globally competitive industry that supports both public health and economic growth.